RedHill Biopharma (NASDAQ:RDHL) Now Covered by StockNews.com

Research analysts at StockNews.com assumed coverage on shares of RedHill Biopharma (NASDAQ:RDHL - Get Free Report) in a research note issued on Saturday. The firm set a "hold" rating on the biotechnology company's stock.

Get RedHill Biopharma alerts:

RedHill Biopharma Stock Down 5.4 %

Shares of RDHL traded down $0.51 during mid-day trading on Friday, reaching $9.02. The company had a trading volume of 114,736 shares, compared to its average volume of 139,887. RedHill Biopharma has a 52-week low of $6.43 and a 52-week high of $82.00. The stock has a 50 day moving average of $225.44 and a two-hundred day moving average of $277.88.

Hedge Funds Weigh In On RedHill Biopharma

An institutional investor recently raised its position in RedHill Biopharma stock. Gagnon Securities LLC boosted its holdings in shares of RedHill Biopharma Ltd. (NASDAQ:RDHL - Free Report) by 32.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 118,360 shares of the biotechnology company's stock after purchasing an additional 28,771 shares during the quarter. Gagnon Securities LLC owned approximately 0.40% of RedHill Biopharma worth $63,000 at the end of the most recent reporting period. Institutional investors own 7.20% of the company's stock.

Ad Porter & Company

My grim warning about AI stocks

Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.

So go here now to read my new report The Big AI Die-Up… while you still can.

About RedHill Biopharma

(Get Free Report)

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.

→ My grim warning about AI stocks (From Porter & Company) (Ad)

Should you invest $1,000 in RedHill Biopharma right now?

Before you consider RedHill Biopharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and RedHill Biopharma wasn't on the list.

While RedHill Biopharma currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report